Praveen MD - Morphic Holding MD CEO
Insider
Praveen MD is MD CEO of Morphic Holding
| Age | 55 |
| Phone | 781 996 0955 |
| Web | https://www.morphictx.com |
Morphic Holding Management Efficiency
The company has return on total asset (ROA) of (0.1909) % which means that it has lost $0.1909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2669) %, meaning that it created substantial loss on money invested by shareholders. Morphic Holding's management efficiency ratios could be used to measure how well Morphic Holding manages its routine affairs as well as how well it operates its assets and liabilities.Morphic Holding currently holds 2.34 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Morphic Holding has a current ratio of 20.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Morphic Holding's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Vaxcyte | 63 | |
| Martin MD | Ventyx Biosciences | 49 | |
| Melissa Abel | 89bio Inc | N/A | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Bahija Jallal | Immunocore Holdings | 64 | |
| MA MS | Inozyme Pharma | N/A | |
| Jeff Fairman | Vaxcyte | 60 | |
| MS MBA | Inozyme Pharma | 48 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Brian MBA | Immunocore Holdings | 58 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Ashish MBA | Vaxcyte | 53 | |
| Grant MBA | Vaxcyte | 57 | |
| Clayton Robertson | Immunocore Holdings | N/A | |
| Craig Muir | Pliant Therapeutics | N/A | |
| Path FRCP | Revolution Medicines | 61 | |
| Teresa McCarthy | Avidity Biosciences | 61 | |
| Rohan Palekar | 89bio Inc | 59 | |
| Michelle Gilson | Arcellx | 32 | |
| Margaret JD | Revolution Medicines | 62 | |
Management Performance
| Return On Equity | -0.27 | |||
| Return On Asset | -0.19 |
Morphic Holding Leadership Team
Elected by the shareholders, the Morphic Holding's board of directors comprises two types of representatives: Morphic Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Morphic. The board's role is to monitor Morphic Holding's management team and ensure that shareholders' interests are well served. Morphic Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Morphic Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CFO COO | ||
| Farrell CPA, Sr Officer | ||
| Simon MBBS, Chief Officer | ||
| Joanne Gibbons, Senior Affairs | ||
| CPA Farrell, Senior Officer | ||
| Aaron Pelta, Senior Development | ||
| Dr MBA, Independent Founder | ||
| Bruce Rogers, President Officer | ||
| Praveen MD, MD CEO | ||
| Timothy Springer, Independent Founder | ||
| Blaise Lippa, Chief Officer | ||
| William Esq, General Secretary |
Morphic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Morphic Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 50.22 M | |||
| Shares Owned By Insiders | 17.12 % | |||
| Shares Owned By Institutions | 91.02 % | |||
| Number Of Shares Shorted | 1.9 M | |||
| Price To Earning | (6.19) X | |||
| Price To Book | 4.63 X | |||
| Price To Sales | 2,753 X |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Morphic Stock
If you are still planning to invest in Morphic Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Morphic Holding's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |